372P Is capecitabine (CAPE) the best treatment (trt) option for estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (MBC) after progression on endocrine treatment (ET): An analysis of the ESME real-world database.
Saved in:
| Title: | 372P Is capecitabine (CAPE) the best treatment (trt) option for estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (MBC) after progression on endocrine treatment (ET): An analysis of the ESME real-world database. |
|---|---|
| Authors: | Pflumio, C.1 (AUTHOR), Carton, M.2 (AUTHOR), Debled, M.3 (AUTHOR), Cottu, P.H.4 (AUTHOR), Leheurteur, M.5 (AUTHOR), Dalenc, F.6 (AUTHOR), Jacot, W.7 (AUTHOR), Mailliez, A.8 (AUTHOR), Sauterey, B.9 (AUTHOR), Levy, C.10 (AUTHOR), Kaderbhai, C.11 (AUTHOR), Tredan, O.12 (AUTHOR), Gonçalves, A.13 (AUTHOR), Uwer, L.14 (AUTHOR), Robert, M.15 (AUTHOR), Bailleux, C.16 (AUTHOR), Cabel, L.4 (AUTHOR), Delaloge, S.17 (AUTHOR), Bosquet, L.18 (AUTHOR), Petit, T.1 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS374-S375. 2p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 179691730 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 372P Is capecitabine (CAPE) the best treatment (trt) option for estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (MBC) after progression on endocrine treatment (ET): An analysis of the ESME real-world database. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Pflumio%2C+C%2E%22">Pflumio, C.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Carton%2C+M%2E%22">Carton, M.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Debled%2C+M%2E%22">Debled, M.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cottu%2C+P%2EH%2E%22">Cottu, P.H.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Leheurteur%2C+M%2E%22">Leheurteur, M.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dalenc%2C+F%2E%22">Dalenc, F.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Jacot%2C+W%2E%22">Jacot, W.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mailliez%2C+A%2E%22">Mailliez, A.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sauterey%2C+B%2E%22">Sauterey, B.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Levy%2C+C%2E%22">Levy, C.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kaderbhai%2C+C%2E%22">Kaderbhai, C.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tredan%2C+O%2E%22">Tredan, O.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gonçalves%2C+A%2E%22">Gonçalves, A.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Uwer%2C+L%2E%22">Uwer, L.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Robert%2C+M%2E%22">Robert, M.</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bailleux%2C+C%2E%22">Bailleux, C.</searchLink><relatesTo>16</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cabel%2C+L%2E%22">Cabel, L.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Delaloge%2C+S%2E%22">Delaloge, S.</searchLink><relatesTo>17</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bosquet%2C+L%2E%22">Bosquet, L.</searchLink><relatesTo>18</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Petit%2C+T%2E%22">Petit, T.</searchLink><relatesTo>1</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2024 Supplement 2, Vol. 35, pS374-S375. 2p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=179691730 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2024.08.320 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 2 StartPage: S374 Titles: – TitleFull: 372P Is capecitabine (CAPE) the best treatment (trt) option for estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (MBC) after progression on endocrine treatment (ET): An analysis of the ESME real-world database. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Pflumio, C. – PersonEntity: Name: NameFull: Carton, M. – PersonEntity: Name: NameFull: Debled, M. – PersonEntity: Name: NameFull: Cottu, P.H. – PersonEntity: Name: NameFull: Leheurteur, M. – PersonEntity: Name: NameFull: Dalenc, F. – PersonEntity: Name: NameFull: Jacot, W. – PersonEntity: Name: NameFull: Mailliez, A. – PersonEntity: Name: NameFull: Sauterey, B. – PersonEntity: Name: NameFull: Levy, C. – PersonEntity: Name: NameFull: Kaderbhai, C. – PersonEntity: Name: NameFull: Tredan, O. – PersonEntity: Name: NameFull: Gonçalves, A. – PersonEntity: Name: NameFull: Uwer, L. – PersonEntity: Name: NameFull: Robert, M. – PersonEntity: Name: NameFull: Bailleux, C. – PersonEntity: Name: NameFull: Cabel, L. – PersonEntity: Name: NameFull: Delaloge, S. – PersonEntity: Name: NameFull: Bosquet, L. – PersonEntity: Name: NameFull: Petit, T. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2024 Supplement 2 Type: published Y: 2024 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 35 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
